Souhaitez-vous accéder aux communiqués récents ?

This industry-first financial innovation bypasses PBM spread pricing, ensures ERISA compliance, gives employers total control over the Budget, Behavior, an

Placebo-adjusted mean weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks with no evidence of weight loss plateau in ACCESS II, demonstrating highest efficacy among oral...

GLP Diet is a personalized weight loss app supporting GLP-1 meds with tailored meals, workouts, trackers, and expert guidance for fast and lasting results.

Omada Health announces GLP-1 Flex Care, giving employers a new, flexible path to support obesity care

Omada Health Reports Fourth Quarter and Full-Year 2025 Results

MindRank, artificial intelligence (AI)-empowered drug discovery company, announced FPI in Phase III Trial of an Oral GLP-1 Receptor Agonist MDR-001.

PETACH TIKVA, Israel, Feb. 25, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes...

GLP-1 use up 67% as bariatric surgeries fall 13%; lower annual costs, but long-term benefits and adherence remain uncertain.

LONDON, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Reset Health (“the Company”), the experts in the personalised management of chronic disease, today announces Pinder Sahota has joined the Company as a...

Kailera and Hengrui report positive topline data from Hengrui’s Phase 2 clinical trial of oral ribupatide, a GLP-1/GIP receptor dual agonist peptide.